Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 29:29:e01591.
doi: 10.1016/j.idcr.2022.e01591. eCollection 2022.

Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients

Amaylia Oehadian  1   2 , Prayudi Santoso  3 , Dick Menzies  4 , Rovina Ruslami  5
Affiliations
Case Reports

Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients

Amaylia Oehadian et al. IDCases. .

Abstract

Linezolid is now recommended as a first line drug for Multidrug Resistant Tuberculosis (MDR-TB). Previous studies reported hematologic toxicity as one of the main side effects. The mechanism of this toxicity is mitochondrial dysfunction, for which a biomarker is Growth differentiation factor-15 (GDF-15). There is no previous report about GDF-15 and its association with hematologic toxicity from Linezolid in the treatment of MDR-TB. We present three cases of MDR-TB involving severe anemia associated with linezolid who had GDF-15 elevation. These cases highlight the need for more research into the relationship between GDF-15 and hematologic toxicity in MDR-TB patients treated with linezolid.

Keywords: Anemia; Case Series; Growth Differentiation Factor-15; Linezolid; Multi-Drug Resistant Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Fig. 1
Fig. 1
Hematology parameter changes over time after starting MDR-TB treatment, A. Hemoglobin level, B. Neutrophil count, C. Platelet count.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization . World Health Organization,; Geneva: 2018. Rapid сOmmunication: Key Changes to Treatment of Multidrug-and Rifampicin-resistant Tuberculosis (MDR/RR-TB)https://apps.who.int/iris/handle/10665/275383 [cited 2021 February 2]. Available from:
    1. Leader R., Hackett J., Allan A., Carter P. Linezolid-induced pancytopenia. Case Rep. 2018 2018:bcr-2018-225480. - PMC - PubMed
    1. Patel M.I., Makhija S.J. Toxicity assessment of linezolid and the beneficial effects of human erythropoietin in mice. Eur J Exp Biol. 2012;2:2172–2181.
    1. Fujita Y., Taniguchi Y., Shinkai S., Tanaka M., Ito M. Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age‐related disorders. Geriatr Gerontol Int. 2016;16:17–29. - PubMed
    1. Wollert K.C., Kempf T., Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 2017;63(1):140–151. - PubMed

Publication types

LinkOut - more resources